Arovella Appoints Acting CEO
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Arovella Therapeutics Limited has appointed Dr. Nicole Van Der Weerden as Acting Chief Executive Officer following the resignation of Dr. Michael Baker. The Chairman, Mr. David Williams, praised Dr. Van Der Weerden's capabilities and assured her of the Board's support during this transition. Dr. Van Der Weerden's salary will be adjusted to match that of her predecessor, and the company will update the market regarding the CEO search process in the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Board Refresh and CEO Resignation
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Arovella Therapeutics
- Clinical manufacturing batch released, first site activated
- The path to first patient dosing
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
- First Patient Dosed with ALA-101
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics